The rising cost of healthcare has increased the importance of health technology assessment (HTA) to support decisions about the regulation of technologies as well as allocation and utilisation of healthcare resources. We will examine the clinical, economic, social and ethical implications of the diffusion and use of medical technology in healthcare. We will cover a broad range of technologies including preventive, diagnosis and therapeutic programs, but also clinical pathway and healthcare organisation.
HTA is an active and multi-disciplinary field that intends to provide a bridge between the world of research and the world of decision-making in health policy. Regulation of technologies is more country-specific and deals with decisions of admission to market and reimbursement by insurance companies. Introduction of new technology to market and eventually coverage by insurance follows a number of rules and conditions that are intended to guarantee efficacy and safety, and control price. Considered as hurdles by the biomedical industry, they represent an evolving compromise between opposing interests. One day synopsis will be dedicated to lectures and cases brought by guests from the healthcare private industry.